Overview

24-hour Efficacy of AR-12286

Status:
Completed

Trial end date:
2012-08-01

Target enrollment:

Participant gender:

Summary

An open-label, non-comparative, pilot evaluation of the 24-hour ocular hypotensive efficacy of AR-12286 in patients with open-angle glaucoma or ocular hypertension

Phase:

Phase 2

Details

Lead Sponsor:

Aerie Pharmaceuticals

Treatments:

Ophthalmic Solutions